Affimed
Bookmark
ShareCopied to clipboardAffimed is a company. It is a public company in Mannheim, Germany. It was founded in 2000 and its current CEO is Mary Beth Sandin. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Mannheim
- country: Germany
- employees: 76 people
- revenues: 6.1M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2000
- CEO: Mary Beth Sandin
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Affimed:
Dataset of stocks from Affimed:
Affimed is one of the companies in Germany, companies in Biotechnology, companies in Health Care, companies in Mannheim and 3,456,808 companies in our database.
Talking Points
- HomepageAffimed
- Affimed (AFMD) is pioneering a transformative innate immunity therapeutic approach to eradicating solid and hematologic tumors to help patients fight cancer.
- Actualizing the untapped potential of the innate immune system | Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform predictably generates customized ...
- Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.